



January 23, 2019

Materials Licensing Branch
United States Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.
+1.317.276.2000
www.lilly.com

RADIOACTIVE MATERIALS LICENSE NUMBER: 13-01133-02
RE: Additional survey clarification for Amendment 71

Peter,

This letter is in response to our phone conversation of January 22, 2019 and your request for additional information with regard to the closeout surveys performed for Amendment 71 requesting removal of Elanco World Headquarters from our Broad Scope license.

Clarification of Survey Process

As mentioned in the meeting, the entire lab space was surveyed and all surveys consisted of 1) a scan with a GM survey meter and 2) large area wipe tests. Any areas identified as contaminated by a wipe test (there were no recorded measurements above background identified with the GM survey meter) were decontaminated to background levels and a GM scan and additional wipe tests were taken to ensure the area was free from fixed or removable contamination. Decontamination persisted until everything remaining in the facility was below levels listed in Regulatory Guide 1.86, Table 1 as listed in our license.

Ventilation/exhaust system and drainage

There was a fume hood in A116 that when surveyed with GM meter and wipe tests showed no fixed or removable contamination. There was no fume hood in A117, but a balance enclosure allowed air to be exhausted after filtration. Items not decontaminated were removed and disposed of as radioactive waste (i.e., balance enclosure filter, enclosure ventilation ductwork). GM Meter and wipe test surveys of the remaining ductwork, orbital strobe, and roof indicated no fixed or removable contamination. There were no drains or sewer disposal at the Elanco facility.

Please contact me if you have additional questions.

Trenton L. Mays, M.S., CHP
Radiation Safety Officer
Telephone: 317-276-2747
Email: t.mays@lilly.com

enclosure

Song, Taehoon

From: Forster, Sara
Sent: Thursday, January 24, 2019 8:50 AM
To: Song, Taehoon; Pavon, Sandy; Sandrik, Lauren
Cc: Tomczak, Tammy
Subject: FW: Phone Call follow-up - Additional Information Request concerning Eli Lilly and Company, NRC Lic. No. 13-01133-02, CN610300
Attachments: NRC Amendment 71 Additional Survey Clarification Jan 2019.pdf

Please scan in the attached letter and return to me. It is additional information as noted above. Thank you!

Sara Forster

From: Lee, Peter
Sent: Thursday, January 24, 2019 8:25 AM
To: Forster, Sara <Sara.Forster@nrc.gov>
Subject: FW: Phone Call follow-up

Hi Sara,

Enclosed is the response from licensee. I have no further concerns.

Peter

From: Trenton L. Mays [<mailto:t.mays@lilly.com>]
Sent: Wednesday, January 23, 2019 10:31 AM
To: Lee, Peter <Peter.Lee@nrc.gov>
Cc: Trenton L. Mays <t.mays@lilly.com>
Subject: [External_Sender] Phone Call follow-up

Hi Peter,

Thanks for taking time to talk with us yesterday. I have attached a clarification for our survey process and the exhaust/drain information – I think it covers the content of our discussion.

Let me know if there is additional information required.

Thanks,
Trent

Trenton L. Mays, M.S., CHP
Manager Radiation Safety, Env Risk Assessment, and Global Hazcom
Eli Lilly and Company
Lilly Corporate Center, Indianapolis IN 46285 U.S.A.
+1 317.276.2747 (office) | +1 317.601.8998 (mobile)
t.mays@lilly.com | www.lilly.com

